The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Nosulya E.V.
Sverzhevky Research Clinical Institute of Otorhinolaryngology
Kim I.A.
N.I. Pirogov Russian National Research Medical University;
National Medical Research Center of Otorhinolaryngology of Federal Medical-Biological Agency
Kunelskaya V.Ya.
L.I. Sverzhevskiy Research Institute of Clinical Otorhinolaryngology
Luchsheva Yu.V.
Sverzhevsky Research Clinical Institute of Otorhinolaryngology
Advanced Therapy of Allergic Rhinitis: Possibilities, Limitations and Prospects
Journal: Russian Rhinology. 2023;31(1): 54‑59
Views: 1384
Downloaded: 33
To cite this article:
Nosulya EV, Kim IA, Kunelskaya VYa, Luchsheva YuV. Advanced Therapy of Allergic Rhinitis: Possibilities, Limitations and Prospects. Russian Rhinology.
2023;31(1):54‑59. (In Russ.)
https://doi.org/10.17116/rosrino20233101154
The lack of efficacy of initial monotherapy for allergic rhinitis (AR) and the absence of an acceptable level of symptom control are observed in clinical practice, which emphasizes the necessity to find and use more effective options for AR treatment.
Data analysis and summary of possibilities and limitations of advanced options for AR therapy
Analysis of PubMed publications (articles and corresponding abstracts) was performed. The information was chosen according to the following keywords: fixed combinations, olopatadine, mometasone furoate, levocetirizine, montelukast, control of allergic rhinitis symptoms.
Most of patients with AR who seek medical care have moderate/severe symptoms. Monotherapy inefficiency in the majority of patients with AR, the need for polytherapy, changes in the number of prescriptions during treatment demonstrate the advisability of searching for new approaches in AR treatment.
One of the preferred strategies in AR treatment is the use of fixed dose combinations, either in the form of a nasal spray (olopatadine hydrochloride + mometasone furoate) or in tablet form (levocetirizine dihydrochloride + sodium montelukast), which avoid polypragmasia and provide faster and more complete control of AR symptoms than current first-line monotherapy.
Keywords:
Authors:
Nosulya E.V.
Sverzhevky Research Clinical Institute of Otorhinolaryngology
Kim I.A.
N.I. Pirogov Russian National Research Medical University;
National Medical Research Center of Otorhinolaryngology of Federal Medical-Biological Agency
Kunelskaya V.Ya.
L.I. Sverzhevskiy Research Institute of Clinical Otorhinolaryngology
Luchsheva Yu.V.
Sverzhevsky Research Clinical Institute of Otorhinolaryngology
Received:
10.01.2023
Accepted:
11.01.2023
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.